主页文献库搜索
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly.

Rios(Jonathan J),Paria(Nandina),Burns(Denn... Hum Mol Genet 2013-07-01

...PIK3CA (R115P) present in the patient's affected nerve tissue but not in blood DNA. Sequencing PIK3CA exons identified g...

Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth ...

Baxi(Sangita M),Tan(Wei),Murphy(Sean T),Sm... PLoS One 2013-04-12

...PIK3CA mutations, were most responsive to IGF-I induction resulting in upregulated AKT and p70S6K phosphorylation via PD...

Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian ...

Bozzao(Cristina),Varvara(Dora),Piglionica(... Int J Biol Markers 2013-09-05

...PIK3CA exon 20. The prevalence of BRAF and PIK3CA mutations was significantly higher in patients older than 65 years (p=...

Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resista...

Chandarlapaty(Sarat),Sakr(Rita A),Giri(Dil... Clin Cancer Res 2013-05-28

...PIK3CA in 13 (29%). The combined rate of PTEN loss and PIK3CA mutation in the trastuzumab-refractory tumors was 71% comp...

Topoisomerase II alpha gene amplification is a favorable prognostic factor in...

Fountzilas(George),Christodoulou(Christos)... J Transl Med 2013-04-01

...PIK3CA mutations were identified by single nucleotide polymorphism genotyping. Survival was evaluated from the initiatio...

Papillary thyroid microcarcinoma with fatal outcome: evidence of tumor progre...

Piana(Simonetta),Ragazzi(Moira),Tallini(Gi... Hum Pathol 2013-05-07

...PIK3CA [phosphoinositide-3-kinase, catalytic, alpha polypeptide]) were performed. Interestingly, all 3 cases presented w...

The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.

Slomovitz(Brian M),Coleman(Robert L) Clin Cancer Res 2013-06-11

...PIK3CA may be indicators of sensitivity to PI3K/AKT/mTOR pathway inhibition, while activating KRAS mutations may predict...

Disruption of epithelial architecture caused by loss of PTEN or by oncogenic ...

Berglund(F M),Weerasinghe(N R),Davidson(L)... Oncogene 2013-11-08

Genetic changes in HER2, PTEN, PIK3CA and AKT1 are all common in breast cancer and lead to the elevated phosphorylation ...

Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent ...

Gökmen-Polar(Yesim),Liu(Yi),Toroni(Rachel ... Breast Cancer Res Treat 2013-06-11

...PIK3CA mutations. MLN0128 potently inhibited cell proliferation in various breast cancer cell lines harboring PIK3CA (IC...

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling...

Janku(Filip),Wheler(Jennifer J),Naing(Aung... Cancer Res 2013-02-27

...PIK3CA H1047R mutation compared with patients who had other PIK3CA mutations or patients with wild-type PIK3CA treated o...

上一页 203 204 205 206 207 208 209 210 211 下一页 207 / 共 353

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: product@genelibs.com